Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
리가켐바이오, TROP2 ADC 후보 LCB84 ‘베스트 인 클래스’ 도전...전망은?
리가켐바이오, TROP2 ADC 후보 LCB84 ‘베스트 인 클래스’ 도전...전망은? : ZUM 뉴스
LCB84 확장 카드 통했다! 리가켐바이오 목표가↑
17亿美元：LCB在研Trop2 ADC授权给强生
17亿美元！强生引进一款Trop2 ADC新药医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
기술수출 우등생 레고켐바이오, 다음은 ‘Trop-2 ADC’로 기대 - 팜이데일리
17亿美元！强生引进一款Trop2ADC新药_财富号_东方财富网
리가켐바이오 Trop2 ADC 경쟁력 자신”…2억달러 옵션 행사까지 순항 | 한국경제
[Korean/Global News] LegoChem Biosciences Announces License Agreement ...
레고켐바이오, LCB84(TROP2-ADC) 기술이전 체결
레고켐바이오, Trop-2 ADC 경쟁약물 대비 효과적일 것 | 한국경제
17 亿美元！强生与LegoChem就Trop2 靶向ADC的达成许可协议 - 知乎
CORRECTING and REPLACING LegoChem Biosciences Announces License ...
Abstract 328: LCB84, a TROP2-targeted ADC, for treatment of solid ...
레고켐바이오, '큰 장' 열린 Trop-2 ADC서 일보 전진
17亿美元！强生引进一款Trop2 ADC医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
LegChem Bio has entered into a licensing deal for their Trop2-focused ...
Abstract 5804: Preclinical evaluation of LCB84, a novel next-generation ...
레고켐바이오, LCB84(TROP2-ADC) 기술이전 계약
Innovation Centers | Johnson & Johnson Innovation
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of ...
ADC赛道新宠靶向『Trop2』药物跨多癌种，后线治疗客观缓解率近40%__凤凰网
레고켐바이오, Trop-2 ADC 항암제 LCB84’ 美 1·2상 신청 | 한국경제
TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other ...
国内第五家，Trop2-ADC获批临床|乳腺癌|转移性|ADC|肿瘤|阴性|药物|疗法|治疗|-健康界
(LCB-84) - 药物靶点：Trop-2 x Tubulin_在研适应症：实体瘤，非小细胞肺癌，胰腺导管癌_专利_临床_研发
A new TROP2-targeting antibody-drug conjugate shows potent antitumor ...
Frontiers | Advances in Trop-2 targeted antibody-drug conjugates for ...
浅谈ADC 药物和Trop-2靶点 抗体偶联药物（Antibody–Drug Conjugates，ADC）是近年来各大药企合作和并购的焦点 ...
Trop2-targeted therapy in breast cancer - PMC
TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical ...
TROP2-ADC正式登陆中国指南！抗晚期TNBC利剑出鞘 | CSCO BC 2022系列-咚咚肿瘤科
TROP-2 Directed Antibody-Drug Conjugates: Clinical Pipeline | stellarix
리가켐바이오, ‘LCB84’ 가치↑…내년 2600억원 확보 기대되는 이유
泛癌种靶点新星—TROP2 - 知乎
Trop2-targeted therapies in solid tumors: advances and future directions
레고켐바이오, 얀센에 2조2460억원 규모 'Trop2-ADC' 기술수출 '잭팟'
Full article: Antibody-drug conjugates (ADCs) targeting TROP-2 in lung ...
RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with ...
Anti-TROP2 mAb for ADC | InvivoGen
TROP-2 ADC 伴随诊断开发，为什么首选免疫组织化学法？ - 知乎
17亿美元：LCB在研Trop2 ADC授权给强生 Armstrong 2023年12月26日，韩国生物技术公司LegoChemBio宣布与 ...
High-quality ADC Target Proteins | Sino Biological
Investigators Lay Groundwork for Exploring TROP-2 as a Therapeutic ...
리가켐바이오 LCB84의 모든 것, 트로델비를 넘어설까? : 네이버 블로그
Trop2 inhibition suppresses the proliferation and invasion of laryngeal ...
리가켐바이오, ‘LCB84’ 가치↑…내년 2600억원 확보 기대되는 이유 - 팜이데일리
靶向TROP-2 ADC药物的临床进展|中性粒细胞|ADC|乳腺癌|靶向|药物|毒性|抗体|-健康界
"레고켐바이오, Trop-2 ADC 경쟁약물 대비 효과적일 것"
杭州多禧生物TROP-2-ADC获批临床，为国内第三 - 癌症123
TROP2靶点介绍及药物研究进展-缔码生物
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer ...
差异化Trop2 ADC：推动肺癌、乳腺癌临床新标准 Armstrong 2024年的ASCO，ADC的临床进展仍然是业界关注的焦点，众多靶点 ...
Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs
续写为何第一三共的Trop2 ADC肺癌坎坷，科伦可能逆袭？ 同步发送至雪球专栏上，得到一位球友的回复，看完有种酣畅淋漓的感觉，与我的想法 ...
新型ADC药物=肺癌患者新希望？来看看TROP2、CEACAM5、c-MET ADC药物的表现！-觅健
김용주 레고켐바이오 대표, "고형암 치료제 "LCB84 다음달 첫 환자 투여"/한국경제TV뉴스 - YouTube
TROP2 is highly expressed in triple-negative breast cancer CTCs and is ...
'13번째 기술수출 목표는 제값받기'...레고켐바이오, 임상 거치면 잭팟 - 팜이데일리
TROP2 is epigenetically inactivated and modulates IGF-1R signalling in ...
Shedding light on triple-negative breast cancer with Trop2-targeted ...
Full article: Current Status and Future Prospects of TROP-2 ADCs in ...
[속보] 국가신약개발사업단, 레고켐바이오 LCB84(Trop2-ADC) 국가신약개발사업 과제 선정 - 헬스코리아뉴스
리가켐바이오 : 우리나라 첫 ADC 글로벌 바이오텍 : 네이버 블로그
Clinical Data on TROP2-Targeting ADCs in Breast, Urothelial, and Lung ...
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect ...
[리가켐바이오] LCB84. LCB14 4분기 임상결과공개! 알테오젠을 놓쳤다면, 다음은 리가켐바이오! 제2의 알테오젠 리가켐 ...
레고켐바이오 'LCB84' 기술이전 비결은?..."현존 ADC 중 높은 효과, 낮은 독성" : 네이버 블로그
Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer ...
Trop-2靶点的ADC药物研发进展 由于Trop-2在多种实体肿瘤中高表达的特性，目前已成为研究人员开发ADC的新靶点。ADC已被视为对付 ...
国产TROP2-ADC疗法攻坚「最凶」乳腺癌III期成功！大热赛道硝烟渐起… | 新药网
Antibody Drug Conjugate Services | Biocytogen
Novel ADC Appears to Leverage TROP2 Expression in NSCLC
深度挖掘Trop2 ADC——从生物学机制到临床开发现状-重组蛋白＆抗体药物-蒲公英 - 制药技术的传播者 GMP理论的实践者
Antibody Drug Conjugate (ADC) Discovery & Proof-of-Concept services
阿斯利康/第一三共Trop2-ADC药物在三阴性乳腺癌响应率达43％ - 知乎
The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate ...
直击WCLC现场TROP2 ADC研究进展，Dato-DXd联合模式或将成为NSCLC一线治疗新选择_队列_患者_TROPION-Lung
LCB-84 - Drug Targets, Indications, Patents - Synapse
레고켐바이오, ADC TROP2 3순위로 성큼…기술수출 기대감↑ | 한국경제
Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current ...
레고켐, 'TROP2 ADC' TOPI 불응서 효능.."5월 美 IND" - 바이오스펙테이터
Part 2: ADCs Targeting TROP2 in NSCLC: Overview and Recent Data - YouTube
Current status and future prospects of TROP-2 ADCs in lung cancer diag ...
Antibody-drug conjugates targeting Trop-2: Clinical developments in ...
레고켐바이오, 얀센에 LCB84(TROP2-ADC) 기술이전 계약 체결
레고켐바이오, LCB84(TROP2-ADC) 기술이전 계약 체결
[단독] 레고켐바이오 'LCB84' 기술이전 비결은?..."현존 ADC 중 높은 효과, 낮은 독성" | YoungSung Lee
.jpg)
